颠覆减肥药赛道！Nature重磅揭示：这种体内天然分子或将改写司美格鲁肽霸权，零副作用抑制食欲效果震撼

Core Viewpoint - The article discusses the discovery and potential of a new anti-obesity peptide called BRP (BRINP2-related peptide), which shows promise in reducing food intake and body weight without causing adverse effects, marking a significant advancement in obesity treatment [7][12][20]. Group 1: Discovery of BRP - BRP was identified by a research team at Stanford University using artificial intelligence, demonstrating its effectiveness in reducing food intake in mouse and pig models without causing nausea [7][12]. - The peptide is derived from the BRINP2 protein and consists of 12 amino acids, showing a significant increase in Fos expression in neuronal cells, indicating its biological activity [12][13]. Group 2: Mechanism of Action - BRP operates through the CREB-FOS signaling pathway in the central nervous system, specifically activating neurons in the hypothalamus, which is crucial for appetite regulation [20][22]. - The peptide's action is independent of leptin, GLP-1 receptor, and melanocortin 4 receptor signaling pathways, highlighting its unique mechanism [7][20]. Group 3: Efficacy and Safety - In studies, BRP significantly reduced food intake in mice, with a dose of 5 mg/kg leading to a notable decrease in consumption, while a higher dose of 20 mg/kg nearly completely suppressed food intake [12][13]. - Importantly, BRP did not induce adverse reactions such as nausea or aversion, which are common side effects associated with other weight loss treatments [14][20]. Group 4: Comparative Effectiveness - In a pig model, BRP demonstrated a 50% reduction in food intake within one hour of administration, comparable to the effects of GLP-1 receptor agonists like liraglutide [15][17]. - Over a 14-day treatment period in obese mice, BRP led to a significant reduction in body weight and improved glucose and insulin tolerance, primarily through fat loss rather than muscle mass reduction [17][20]. Group 5: Future Implications - The research presents BRP as a potential therapeutic agent for obesity, offering a new avenue for treatment that may be free from the side effects associated with current obesity medications [22].